NCT04847050: A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

NCT04847050
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with a history of leptomeningeal disease; Patients with a known history of the SARS-CoV-2 infection; Patients who have received an investigational coronavirus (e.g., SARS-CoV-2, SARS-CoV, MERS-CoV) vaccine
https://ClinicalTrials.gov/show/NCT04847050

Comments are closed.

Up ↑